Business context and reporting period
Autonomix Medical, Inc. is a pre-revenue, clinical-stage medical-device company developing technology to sense and treat peripheral nervous system disorders. This unaudited Form 10-Q reports the three and nine months ended December 31, 2023, the company’s fiscal third quarter and year-to-date period.
The company is developing a catheter-based platform, initially targeting pain associated with pancreatic cancer and pancreatitis. It reported animal-study results but had not established safety or effectiveness in human clinical trials.
Financial performance and position
Unless otherwise noted, amounts are in millions of dollars. The company reported no revenue in the periods presented.
| Metric | Three months ended Dec. 31, 2023 | Nine months ended Dec. 31, 2023 | Comparable 2022 period |
|---|---|---|---|
| Operating expenses | $2.924 | $9.614 | $0.544 / $1.333 |
| Net loss | $3.113 | $10.018 | $0.544 / $1.333 |
| Loss per share, basic and diluted | $0.23 | $0.74 | $0.05 / $0.11 |
| Net cash used in operating activities | Not provided for quarter | $4.361 | $1.234 used |
At December 31, 2023, cash was $1.218 million, working capital was approximately $0.7 million, and total assets were $1.809 million. Current liabilities were $0.973 million. Long-term liabilities included a $4.974 million warrant liability and convertible notes with a $1.457 million net carrying amount ($2.0 million principal less unamortized discount). Stockholders’ deficit was $5.595 million. Profitability and operating margins are not applicable because the company had no revenue and incurred operating losses.
Nine-month financing provided $4.730 million net cash: $2.840 million from common-stock sales and $2.0 million from convertible notes, offset by $0.110 million of offering costs. Investing activities used $0.016 million.
Material changes versus the prior comparable periods
- Operating expenses rose 438% in the quarter and 621% year to date. General and administrative expense increased primarily due to IPO-related advertising, expanded management compensation, stock-based compensation, and professional fees.
- Research and development expense increased to $0.601 million for the quarter and $1.384 million year to date, mainly reflecting clinical-trial planning and development costs.
- Year-to-date results included a noncash $4.556 million warrant expense related to a license termination agreement, plus $0.418 million of warrant-liability remeasurement expense. These items had no comparable expense in 2022.
- Operating cash use increased to $4.361 million from $1.234 million in the prior-year nine-month period.
Outlook, risks, contingencies and unusual items
- Going concern: Management stated that recurring losses and cash outflows raise substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements. It expects losses for several years and does not expect near-term positive operating cash flow.
- Funding: The company estimated that, including IPO proceeds, available cash would fund operations into but not beyond the first calendar quarter of 2025. It estimated needing an additional $10 million to $40 million to fund operations during clinical trials; financing availability and timing are uncertain. Failure to raise funds could require reduced operations or a scaled-back business plan.
- Subsequent IPO: On January 26, 2024, after quarter-end, the company sold 2,234,222 shares at $5 per share for $11.2 million gross and $9.8 million net proceeds. A portion of convertible notes converted into 335,000 shares; $1.3 million principal remained outstanding due to a 4.99% beneficial-ownership limit.
- Related-party warrant: On January 29, 2024, the company issued a warrant for 1.6 million shares under a license termination agreement with a company controlled by a significant stockholder. The agreement set an $8.0 million fixed value for the warrant and had generated the $4.556 million expense and $4.974 million year-end liability. The warrant shares are subject to lockups and resale-registration obligations.
- Execution and dilution risks: Clinical results, regulatory clearance, manufacturing and supply, commercialization, and future financing remain uncertain. The filing also describes potentially dilutive options, warrants and convertible securities; approximately 1.8 million warrants were exercised cashlessly in January and February 2024.
- Controls: Management concluded disclosure controls were ineffective at December 31, 2023. Material weaknesses included complex debt and equity accounting, limited segregation of duties, financial reporting and technology controls, and earnings-per-share computations. The company reported adding experienced executives and outside consultants to address deficiencies.
- The filing reported no material pending litigation and no material change to the risk factors previously set out in its offering circular. It provided no revenue or earnings guidance.
Important facts for investors to verify
- Whether post-IPO cash and subsequent spending support the stated runway, and whether additional financing will be needed sooner than expected.
- Clinical-trial plans, timelines, costs, results and regulatory milestones for the company’s initial indications.
- The remaining convertible-note balance, conversion terms, warrant exercises and resulting share dilution.
- The valuation, share issuance and registration obligations associated with the $8.0 million related-party termination-agreement warrant.
- Progress in remediating the disclosed material weaknesses and restoring effective disclosure and financial-reporting controls.